AVA-011

N/A

Report date: 2024/08/15 14:19:47

Base Information

Drug NameAVA-011

Drug Alias NameAVA-011

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocytes stimulants

TargetsUpdating

Therapy Area/IndicationsLymphoma, Non-HodgkinPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAvalon Globocare Corp

China Registration ClassN/A

Develop Information

Active CompaniesAvalon Globocare Corp

Inactive CompaniesN/A

Active IndicationsLymphoma, Non-HodgkinPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A